We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Exenatideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Exenatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2017 with a typical study size of 377 participants.
Based on 12 studies · 3 meta-analyses · 9 RCTs · 18,216 total participants
Confidence
HighBy outcome
Exenatide has an evidence score of 6/10 — moderate evidence based on 12 indexed studies, including 3 meta-analyses. The first-in-class GLP-1 receptor agonist — an FDA-approved prescription drug for type 2 diabetes (Byetta twice-daily, Bydureon once-weekly). Honest appraisal: it genuinely lowers HbA1c and produces modest weight loss in solid phase-3 RCTs (the DURATION program), but its dedicated cardiovascular-outcomes trial, EXSCEL, was NEUTRAL on its primary endpoint (HR 0.91, P=0.06 for superiority). It is older and less potent than newer agents (liraglutide beat it head-to-head; semaglutide and tirzepatide are stronger still), and it is increasingly superseded in practice. Listed here for reference only — a prescription medicine, not a supplement, and not auto-recommended. Representative study: PMID 24263424.
The commonly studied dose of Exenatide is Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Exenatide (GLP-1 receptor agonist)
The first-in-class GLP-1 receptor agonist — an FDA-approved prescription drug for type 2 diabetes (Byetta twice-daily, Bydureon once-weekly). Honest appraisal: it genuinely lowers HbA1c and produces modest weight loss in solid phase-3 RCTs (the DURATION program), but its dedicated cardiovascular-outcomes trial, EXSCEL, was NEUTRAL on its primary endpoint (HR 0.91, P=0.06 for superiority). It is older and less potent than newer agents (liraglutide beat it head-to-head; semaglutide and tirzepatide are stronger still), and it is increasingly superseded in practice. Listed here for reference only — a prescription medicine, not a supplement, and not auto-recommended.
An FDA-approved GLP-1 drug with solid phase-3 RCTs showing real HbA1c and modest weight reduction, but its cardiovascular-outcomes trial was neutral and it is less potent than newer agents — hence Moderate, not high.
Exenatide is a synthetic version of exendin-4, a peptide from the Gila monster's saliva that mimics the human incretin hormone GLP-1 (glucagon-like peptide-1). It was the first GLP-1 receptor agonist brought to market (Byetta, approved 2005), later joined by an extended-release once-weekly formulation (Bydureon).
It is a prescription drug, NOT a dietary supplement, approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), the brain (appetite suppression/satiety), and the gut (slowed gastric emptying). The efficacy evidence is solid but moderate by modern standards.
The pivotal AMIGO trials showed twice-daily exenatide added to metformin or a sulfonylurea reduced HbA1c by ~0.8% with dose-dependent weight loss (DeFronzo 2005; Buse 2004).
The DURATION program then established the once-weekly formulation: DURATION-1 showed once-weekly beat twice-daily on HbA1c (-1.9% vs -1.5%); DURATION-3 maintained an HbA1c edge over insulin glargine at 3 years with weight loss instead of weight gain; DURATION-2 beat sitagliptin and pioglitazone.
The honest counterweight is potency and outcomes. Head-to-head, liraglutide lowered HbA1c more than exenatide twice-daily (LEAD-6) and matched once-weekly exenatide while being better tolerated (DURATION-6, where exenatide did NOT meet non-inferiority vs liraglutide).
Most importantly, the dedicated cardiovascular-outcomes trial EXSCEL (14,752 patients) was NEUTRAL: the primary MACE composite was non-inferior for safety but NOT superior for efficacy (HR 0.91; 95% CI 0.83-1.00; P=0.06 for superiority) — in contrast to liraglutide (LEADER), semaglutide (SUSTAIN-6/SELECT), and dulaglutide (REWIND), which all showed significant cardiovascular benefit.
Newer GLP-1 agents are more potent on glycemia and weight, simpler to dose, and carry proven cardiovascular benefit, so exenatide is increasingly a legacy option.
Safety mirrors the class: a boxed warning for thyroid C-cell tumors, risks of pancreatitis and gallbladder disease, very common GI side effects, dose adjustment/avoidance in renal impairment, and injection-site reactions (more with the once-weekly depot).
It should be used only under a clinician's care for a genuine medical indication, and compounded/grey-market exenatide should be avoided.
A synthetic exendin-4 peptide (the first-in-class GLP-1 receptor agonist) that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake, contributing to the modest weight loss seen across the AMIGO and DURATION trials.
Delays gastric emptying — blunting post-meal glucose excursions (especially with twice-daily dosing) and prolonging fullness — and the mechanism behind much of the nausea.
How Exenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.
Loading: Twice-daily exenatide is started at 5 µg before meals and increased to 10 µg after about a month to limit GI side effects. The once-weekly form is given as a fixed 2 mg weekly depot. Titration is done under clinician supervision.
Can be taken without food
| Form | Type |
|---|---|
| 💊Once-weekly extended-release injection (Bydureon) | Recommended |
| 💊Twice-daily injection (Byetta) | Alternative |
The once-weekly depot gives better HbA1c than twice-daily and is more convenient, at the cost of more injection-site nodules. Both are increasingly superseded by newer, more potent GLP-1 agents. Avoid compounded/grey-market exenatide — use only pharmacy-dispensed product.
Minimum: 12 weeks
Optimal: 26 weeks
Cycling: Not required
Note: Twice-daily (Byetta): inject within 60 minutes before the two main meals. Once-weekly (Bydureon): inject on the same day each week, any time, with or without food. Dosing is set and titrated by the prescribing clinician — never self-escalate.
Dose-response data unavailable. The current published research for Exenatide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Consistent HbA1c reductions (~0.8% twice-daily, ~1.3-1.9% once-weekly) across the AMIGO and DURATION phase-3 programs. Effective, but less than liraglutide head-to-head.
Dose-dependent weight reduction (typically ~1.5-3 kg) rather than weight gain — smaller than the double-digit percentages seen with newer agents like semaglutide and tirzepatide.
Unlike liraglutide, semaglutide and dulaglutide, exenatide's dedicated outcomes trial (EXSCEL) did NOT meet superiority for major adverse cardiovascular events (HR 0.91; 95% CI 0.83-1.00; P=0.06). It was safe, not protective.
Nausea, vomiting and diarrhea are the most frequent adverse events — usually mild-to-moderate and transient, decreasing over time, but a common reason for discontinuation.
The once-weekly depot (Bydureon) is associated with injection-site nodules/induration more often than the twice-daily form.
Contraindicated — class boxed warning for thyroid C-cell tumors.
Use with caution; avoid in severe impairment (eGFR <30) and end-stage renal disease — exenatide is renally cleared and there are reports of acute kidney injury.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — not recommended in pregnancy or breastfeeding.
Not appropriate — exenatide is not approved for weight management, and newer agents have far stronger weight-loss evidence. This is a prescription drug with real risks, not a cosmetic shortcut.
Combining with a sulfonylurea or insulin raises hypoglycemia risk; the clinician typically reduces those agents. Exenatide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can slow/reduce absorption of co-administered oral drugs; take time-sensitive oral medicines (antibiotics, oral contraceptives) at least 1 hour before twice-daily exenatide.
Tip: Gradual dose titration; smaller meals; usually transient and decreasing over time
Tip: Slow titration, hydration, dietary adjustment; report severe/persistent symptoms to a clinician
Tip: Rotate injection sites; usually resolves; report persistent or painful nodules
Tip: Reduce sulfonylurea/insulin dose under clinician guidance; carry fast-acting carbohydrate
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Timing is flexible for Exenatide — consistent daily use matters more than the time of day. Twice-daily exenatide (Byetta) is injected within 60 minutes BEFORE the two main meals (not after); the once-weekly form (Bydureon) is injected on the same day each week regardless of meals.
Exenatide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea, injection-site nodules / induration (once-weekly form). Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease — exenatide is renally cleared.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Post-marketing reports of increased INR, sometimes with bleeding, when exenatide is added — monitor INR more closely.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, semaglutide, tirzepatide) — additive risk with no added benefit.
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: More likely with dehydration from GI losses; maintain hydration, monitor renal function, avoid in severe renal impairment